Trexquant Investment LP Makes New $2.46 Million Investment in Boston Scientific Corporation $BSX

Key Points

• Trexquant Investment LP purchased 24,422 shares of Boston Scientific Corporation for approximately $2.46 million during the first quarter of the year.
• Boston Scientific reported a 22.8% increase in revenue year-over-year, with quarterly earnings of $0.75 EPS, surpassing analysts' expectations of $0.72 EPS.
• Currently, institutional investors and hedge funds own 89.07% of Boston Scientific's stock, indicating strong institutional confidence in the company.

Trexquant Investment LP acquired a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 24,422 shares of the medical equipment provider's stock, valued at approximately $2,464,000.

A number of other institutional investors have also recently bought and sold shares of BSX. HM Payson & Co. lifted its stake in Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock worth $694,000 after acquiring an additional 98 shares during the period. Park Square Financial Group LLC raised its position in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after purchasing an additional 103 shares during the last quarter. HHM Wealth Advisors LLC increased its holdings in Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock worth $89,000 after buying an additional 103 shares in the last quarter. Forum Financial Management LP grew its stake in shares of Boston Scientific by 0.8% during the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock valued at $1,357,000 after purchasing an additional 112 shares during the period. Finally, Paladin Wealth LLC grew its stake in shares of Boston Scientific by 1.6% during the 1st quarter. Paladin Wealth LLC now owns 7,156 shares of the medical equipment provider's stock valued at $722,000 after purchasing an additional 113 shares during the period. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Up 0.7%

NYSE BSX traded up $0.74 during mid-day trading on Monday, reaching $107.96. The stock had a trading volume of 4,573,560 shares, compared to its average volume of 7,446,310. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $108.94. The company has a fifty day moving average price of $104.77 and a 200 day moving average price of $102.15. The stock has a market cap of $159.97 billion, a PE ratio of 64.23, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the company posted $0.62 earnings per share. The business's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BSX has been the topic of several analyst reports. Needham & Company LLC reissued a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Truist Financial upped their price objective on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Finally, Wells Fargo & Company increased their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $117.79.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock worth $18,397,457. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.